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Abstract
Clostridium difﬁcile infection is a leading cause of antibiotic-related and healthcare-related diarrhoea. In the past decade, faecal microbiota
transplantation or transfer has attracted increasing interest as an effective treatment strategy for severe recurrent C. difﬁcile infection, with
a global success rate of >80%. However, experience with this procedure is limited by a lack of randomized trials supporting its efﬁcacy and
the lack of standardization of the procedure. This review will address the practical aspects of the protocol.
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Introduction
The goal of faecal microbiota transplantation or transfer (FMT)
is to restore the physiological balance by transferring gut
microbiota from a healthy donor. In the past decade, this
technique has attracted increasing interest as an effective
treatment strategy for severe recurrent Clostridium difﬁcile
infection (CDI) [1–3]. It has been recently shown that FMT has
an immediate and long-lasting reparative effect on the intestinal
microbiota of CDI patients, with a decrease in the level of
C. difﬁcile after transplantation [4]. The FMT leads to a shift
from an ecosystem dominated by potentially harmful bacteria
to a healthy-like microbial proﬁle. In March 2014, the
European Society of Clinical Microbiology and Infectious
Diseases published the ‘Update of the Treatment Guidance
Document for Clostridium difﬁcile Infection’, which strongly
recommended (A-I) faecal transplantation in combination with
oral antibiotic treatment for the treatment of multiple
recurrent CDIs unresponsive to repeated antibiotic treatment
[5]. However, practical aspects regarding the donors,
recipients and physicians were not mentioned.
Furthermore, FMT appears to be a promising treatment in
the setting of other diseases associated with microbial dysbiosis
and whose aetiologies are unknown or uncertain (e.g. inﬂam-
matory bowel disease, irritable bowel syndrome, metabolic
syndrome, and neurodevelopmental disorders) [6] or against
extended-spectrum b-lactamase-producing Enterobacteriaceae
residing in the large intestine, as recently shown [7].
In general practice, experience with this procedure is
limited by a lack of randomized trials supporting its efﬁcacy,
the lack of standardization of the procedure, and the
unappealing nature of the treatment. This review will address
the practical aspects of the protocol.
Regulatory Aspects of FMT
Deﬁning the status of FMT is actually a challenging regulatory
issue. The Food and Drug Administration considers FMT to be
a drug, and released a new guidance for public consultation in
February 2014 [8]. In Europe, the UK’s National Institute of
Health and Care Excellence has stated that it does not
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consider FMT to involve the transplantation of body tissue [9],
and in March 2014 the French regulatory agency (ANSM)
expressly declared it to be a drug [10]. The European
Medicines Agency has not yet promulgated its position. In
contrast, Smith et al. [11] argue that, for medical uses, the
human stool should be considered a tissue, and not a drug.
Classic deﬁnitions are of limited value, as neither ‘tissue’ of
human origin nor ‘conventional drug’ seems to be a relevant
classiﬁcation for a therapy intended for microbiome modula-
tion. Recently, Megerlin et al. suggested that FMT should be
regulated as a sui generis biological drug for the treatment of
severe recurrent CDI without any possible biosimilarity
between lots [12,13].
Practical Aspects of FMT
Although patient perceptions of FMT are positive, navigating
the known and unknown risks remains a major issue for the
clinician managing patients with CDI. Up to now, there has
been no clear consensus on the optimal protocol for faeces
preparation before FMT, even if the donor microbiota is
determinant for the outcome of FMT [4]. Studies have differed
in terms of types of donors and the protocol for their
screening, sample handling and preparation, recipient prepa-
ration, administered quantity, and mode of infusion. However,
the overall reported success rate is >80% [2,3].
Donor selection
Once FMT candidates have been identiﬁed, they are generally
asked to identify a healthy, related faeces donor, as they
share the same environment and life habit, thus limiting the
risk of pathogen transmission [1,2]. Most patients will identify
their spouse or another close family member as a potential
donor. Those who have ineligible family members may
suggest a friend. Unrelated healthy screened donors can also
be selected to facilitate the availability of a faecal sample
[3,14,15]. Not only could the availability of a healthy
pre-screened unrelated donor allow prompt treatment, as
it can take up to 2 weeks to obtain screening laboratory
results, but it could also reduce overall laboratory screening
costs and provide more standardized treatment to patients.
One systematic review provided data to suggest that FMT
with faeces from a related donor (spouse or intimate
partner) yields a somewhat higher rate (93.3%) of CDI
resolution than FMT with faeces from an unrelated donor
(84%) [16]. The work of Fuentes et al. [4] is a ﬁrst step
towards better identiﬁcation of microbial signatures from
donor and patients, which could improve FMT outcome.
Recently, ANSM strongly encouraged the selection of
anonymous donors with regard to French legislation con-
cerning organ donation [10].
Although absolute and relative exclusion criteria can be
identiﬁed for the donor by the use of a questionnaire
(Table 1), transmission of communicable disease remains an
inevitable risk, despite rigorous donor screening for infectious
disease. These risks are well deﬁned in blood transfusion
practice, but they are less clear in FMT, especially as donor
screening protocols vary, widely despite calls for standardiza-
tion [1]. However, it is critically important to give primary
consideration to the severity of the patient’s illness.
Some centres initially screen potential donors either in
person at the patient/recipient visit or via phone interview
with, sometimes, a speciﬁc FMT coordinator using a standard
screening questionnaire. The interview with potential donors
should determine the potential risk of the donor harbouring a
transmissible blood-borne or enteric pathogen. Donors with a
history of high-risk behaviours, incarceration, recent tattooing
or body piercing, illicit drug use or multiple sexual partners are
excluded. Persons with recent international travel to areas at
high risk for enteric infections or multiple drug-resistant
bacteria are excluded. Potential donors with chronic gastro-
intestinal illnesses (Crohn’s disease, ulcerative colitis, irritable
bowel syndrome, and coeliac disease), malignancy or autoim-
mune disorders are also excluded. Some additional aspects
could be considered, such as recent ingestion of a potential
allergen in persons with past allergic reactions to this (these)
allergen(s), diseases potentially associated with or attributable
to microbiota changes, such as major gastrointestinal surgery
(e.g. gastric bypass and short bowel syndrome), metabolic
syndrome, morbid obesity, atopic diseases, including asthma
and eczema, eosinophilic disorders of the gastrointestinal
tract, and chronic pain syndromes (e.g. chronic fatigue
syndrome and ﬁbromyalgia) [1,16,18,19]. Furthermore, poten-
tial donors must not have received antibiotics or chemother-
apy, or have been hospitalized, within 3 months before
donation. Different centres did not specify whether a physical
examination was performed, aside from the questionnaire and
biological testing.
Theoretically, sexually intimate contacts would have previ-
ously shared body ﬂuids and exposure to relevant communi-
cable diseases, so some centres allowed intimate partners to
opt out of testing for blood-borne pathogens, to save costs
and facilitate more rapid performance of FMT.
Screening for pathogens
Regardless of the relationship between the donor and the
recipient, screening for potential blood or faecal pathogens is
always performed. New guidelines have been published in the
last few years [1,10,18]. The precautionary principle stipulates
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that, in order to avoid pathogen transmission, more screening
tests (virus, bacteria, and parasites) are warranted. This has led
to a signiﬁcant increase in screening costs (Table 2). Measure-
ment of faecal calprotectin should also be performed, in order
to exclude potential donors with intestinal mucosal
inﬂammation [20].
Also, the risk non-infectious disease transmission must be
considered, as the gut microbiome has been implicated in
many conditions, ranging from depression to inﬂammatory
bowel disease.
The donor’s microbiota composition seems to impact on
FMT outcome. Although, to date, there is no standardized
microbiota composition testing, it would be a valuable
acquisition in terms of donor screening [4].
Preparation of faeces
The donor has to be told: (i) to notify the practitioner of any
symptoms of infection (fever, diarrhoea, vomiting, etc.)
occurring between screening and the time of donation; and
(ii) to avoid any food to which the recipient may be allergic for
5 days prior to the procedure. The use of a gentle osmotic
laxative the night before the procedure can be considered, to
facilitate bowel movements and manipulation of the sample [1].
On the day of FMT, freshly produced donor faeces (50–200 g)
are processed and infused, preferably within 6 h of passage,
and no more than 24 h after stool donation. All manipulations
of faecal samples should be performed under a hood, and the
operator should wear a ﬂuid-resistant gown, gloves, and a
mask with goggles or an eye-shield when handling or mixing
faecal material, because faeces are rated as a level 2 biohazard.
Whether or not faeces should be prepared in an anaerobic
environment to preserve as many obligate anaerobic bacteria
as possible is unknown. However, most laboratories lack
anaerobic chambers, and the greatest success has been
obtained with aerobic preparations, so the use of a cabinet
under anaerobic gaz phase (N2) seems not to be absolutely
required [15,18]. Faeces are usually dissolved at room
temperature in preservative-free normal saline, but other
vehicles, such as water or 4% milk, have also been described.
Saline and milk may give slightly lower resolution (86.2% and
88.6%, respectively) and recurrence (3.0% and 3.2%, respec-
tively) rates, whereas water may give higher resolution (98.5%)
and recurrence (7.8%) rates [1,16]. Faeces are homogenized in
a dedicated commercial blender, and diluent is added as
necessary, until a liquid slurry consistency is obtained. The
faecal preparation is then passed through ﬁlters (e.g. gauze
pads or a series of stainless steel laboratory sieves) to remove
undigested food and smaller particulate material. Each centre
must deﬁne the conditions of carriage, the room and methods
used for faecal preparation, and the place and conditions of the
TABLE 1. Serological and stool testing for selection of donors
Bakken et al. [1] Van Nood et al. [18] ANSM 2014 [10]a
Blood HIV types 1 and 2
HAV IgM
HBsAg, anti-HBc (both IgG and IgM), and anti-HBs
HCV Ab
RPR and FTA-ABS
Conﬁrmatory tests will be performed when a
positive or reactive screening test result is received
for such purposes as donor counselling or investigating
discordant test results
Serological testing of the recipient for these agents
is optional
HIV types 1 and 2
Human T-lymphotropic virus types I and II
HAV (total antibodies, if positive and
not vaccinated also hepatitis A IgM)
HBV (HBsAg, anti-HbsAg, anti-HBc)
HCV C (anti-HCV)
CMV (IgG and IgM)
EBV (VCA IgM, VCA IgG, VCA, anti-EBNA)
Treponema pallidum (TPHA)
Entamoeba histolytica (agglutination
and dipstick test)
Strongyloides stercoralis (ELISA)
HIV types 1 and 2 (serology and viral load)
Human T-lymphotropic virus
Hepatitis A and B (serology and viral load), hepatitis C
(serology and viral load) and hepatitis E
CMV
EBV (to conﬁrm the absence of any serodiscordance
with the recipient)
Treponema pallidum
Strongyloides stercoralis
Trichinella species
Toxoplasma gondii (to conﬁrm the absence of any
serodiscordance with the recipient)
Faeces Clostridium difﬁcile toxin B by PCR; if unavailable, then
toxin A and B by EIA
Routine bacterial culture for enteric pathogens
Faecal Giardia antigen
Faecal Cryptosporidium antigen
Acid-fast stain for Cyclospora, Isospora and, if antigen
testing unavailable, Cryptosporidium
Ova and parasites
Helicobacter pylori faecal antigen (for upper GI
routes of FMT)
Test for C. difﬁcile (toxin ELISA and
culture or PCR)
Bacteriological evaluation according to
local standards
Parasitological evaluation according to
local standards (triple faeces test or PCR)
Bacterial culture for: C. difﬁcile
Listeria monocytogenes
Vibrio cholerae/Vibrio parahemolyticus
Salmonella
Shigella
Multiresistant bacteria
Strongylo€ıdes stercoralis
Cryptosporidium species
Cyclospora species
Entamoeba histolytica
Giardia intestinalis
Isospora species
Microsporidies
Adenovirus
Astrovirus
Rotavirus
Calcivirus (norovirus, sapovirus)
Picornavirus (enterovirus, Aichi virus)
Ab, antibody; CMV, cytomegalovirus; EBNA, Epstein–Barr virus nuclear antigen; EBV, Epstein–Barr virus; EIA, enzyme immunoassay; FMT, faecal microbiota transplantation;
FTA-ABS, ﬂuorescent treponemal antibody absorption; TPHA, Treponema pallidum particle agglutination assay; GI, gastrointestinal; HAV, hepatitis A virus; HCV, hepatitis C virus;
HIV, human immunodeﬁciency virus; RPR, rapid plasma reagin; VCA, viral capsid antigen.
aThese recommendations have been proposed in the case of clinical trials. In the case of FMT for recurrent Clostridium difﬁcile infection, the strict application of the measures
outlined below is at the discretion of the physician, depending on the emergency of the situation and the expected beneﬁts with regard to the risks associated with FMT.
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administration. Account should be taken of each step, to
enable the patient to receive treatment in time. If necessary,
the FMT transplant may, but need not, be refrigerated for
travel [19].
Recently, data have become available on the use of
standardized frozen faecal samples, and outcomes do not
seem to have been affected by this procedure in case series
[15,21]. The logistic advantage of frozen material stored in
TABLE 2. Questionnaire for
screening potential donors based on
Bakken et al. [1] and the French
regulatory agency (ANSM) [10]
Absolute exclusion criteria
Relative exclusion criteria that it
may be appropriate to consider
Risk of infectious agent
 Known HIV, hepatitis B or hepatitis C infections
 Known exposure to HIV or viral hepatitis
(within the previous 12 months)
 High-risk sexual behaviours (examples: sexual
contact with anyone with HIV/AIDS or
hepatitis, men who have sex with men, sex
for drugs or money)
 Use of illicit drugs
 Tattoo or body piercing within 6 months
 Incarceration or history of incarceration
 Known current communicable disease (e.g. upper
respiratory tract infection)
 Risk factors for variant Creutzfeldt–Jakob disease
 Travel (within the last 6 months) to areas of
the world where diarrhoeal illnesses are endemic
or the risk of traveller’s diarrhoea is high
 History of typhoid fever (French regulatory agency)
 Hospitalization abroad for more than 24 h in the last
12 months (including members of the entourage)
(French regulatory agency)
 Residence for several years in the tropics
(French regulatory agency)
Gastrointestinal comorbidities
 History of inﬂammatory bowel disease
 History of irritable bowel syndrome, idiopathic
chronic constipation, or chronic diarrhoea
 History of gastrointestinal malignancy or known
polyposis
 Acute diarrhoea during the last 3 months
(French regulatory agency)
Gastrointestinal comorbidities
 History of major gastrointestinal surgery
(e.g. gastric bypass and short bowel)
 Family history of inﬂammatory bowel
disease, autoimmune disease. and colonic
cancer (French regulatory agency)
Factors that can or do affect the composition of the
intestinal microbiota
 Antibiotics within the preceding 3 months
 Major immunosuppressive medications, e.g.
calcineurin inhibitors, exogenous glucocorticoids,
and biological agents
 Systemic antineoplastic agents
Factors that can or do affect the composition of
the intestinal microbiota
 Age > 65 years (French regulatory
agency)
 Body mass index of > 30 kg/m2 (French
regulatory agency)
Additional recipient-speciﬁc considerations
 Recent ingestion of a potential allergen (e.g. nuts)
where the recipient has a known allergy to this
(these) agent(s)
Additional recipient-speciﬁc considerations
 Metabolic syndrome
 Systemic autoimmunity, e.g. multiple
sclerosis and connective tissue disease
 Atopic diseases, including asthma and
eczema, and eosinophilic disorders of
the gastrointestinal tract
 Chronic pain syndromes (e.g. chronic
fatigue syndrome and ﬁbromyalgia)
HIV, human immunodeﬁciency virus. The criteria are quite similar in both recommendations. The French regulatory
agency added some criteria to decrease the risk of screening a donor with carriage of multiresistant bacteria.
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advance is obvious, as it can be used directly when necessary,
with a reduction in laboratory screening costs. However, no
storage of >156 days has yet been described [15].
Traceability of all steps of the preparation, from delivery of
faeces to FMT, should be ensured, and ANSM recommends
storing a sample of material delivered by the donor and a
sample of the preparation for FMT for 2 years at 80°C [10].
Recipient preparation
Once the recipient has given written consent, and a suitable
donor has been identiﬁed, the FMT procedure and its
follow-up should be coordinated by the same department, in
order to yield a safe and efﬁcient process.
In all studies, antibiotics against C. difﬁcile, such as vanco-
mycin or metronidazole, were used prior to FMT to suppress
the pathogen burden, and then discontinued the evening
before or 1–3 days before the procedure, which raises a
question about the potential impact of pre-transplantation
antibiotic therapy on the reported high success rates. It was
generally thought that this was unlikely to inﬂuence the results,
because previous courses of vancomycin/metronidazole have
failed in these patients. However, in the absence of a control
group, it is not possible to determine whether the observed
outcomes are the results of the pre-transplantation antibiotic
treatment, the results of FMT alone, or the results of the
combined treatment [18].
Delivery of FMT
There is no general agreement on the best approach for
delivering faecal microbiota or on the optimal volume. FMT is
predominantly performed with a freshly prepared specimen,
with 25–50 mL administered if delivery is by the nasogastric
route, or 250–1000 mL if delivery is by colonoscopy or
retention enema [22]. The authors of the only randomized
published study recommended a treatment combining vanco-
mycin, 500 mg four times daily for 4 days, a bowel lavage, and
nasoduodenal infusion of donor faeces [5]. However, numer-
ous studies have demonstrated the efﬁcacy of colonic FMT.
Lower gastrointestinal FMT via colonoscopy seems to be more
effective than upper gastrointestinal delivery, but randomized
controlled trials are required to conﬁrm this [2].
The different methods for delivery of faeces have several
advantages and disadvantages (Table 3) [23].
Delivery into the stomach or the small bowel via a tube or
gastroscope is pathophysiologically different from delivery into
the colon by colonoscopy or retention enema (Table 3).
Delivery of faecal microbiota via a nasogastric tube requires
less patient preparation, clinical time, patient inconvenience
and cost than via a colonoscopy, and it is technically easier to
perform. This method provides more extensive exposure of
the gastrointestinal tract to the donor faecal microbiota;
however, it may carry the risk of vomiting and potentially
aspirating faecal material. Moreover, it may predispose patients
to bacterial overgrowth, particularly in elderly patients who
are achlorhydric (lack of gastric acid in the stomach) or have a
small-intestine motility disorder. The question of the action of
proton-pump inhibitors, which are frequently used by the
general population, should also be raised.
C. difﬁcile organisms reside throughout the entire colon and
in the terminal ileum, where the vast majority of C. difﬁcile
infestation is established. Colonoscopy allows delivery of a
large volume of faecal suspension throughout the entire colon
and better retention than nasogastric tube or retention enema
delivery. Colonoscopy also allows direct simultaneous inspec-
tion of the colon mucosa, and the determination of preferen-
tial sites for infusing sufﬁcient amounts of donor faeces. In
addition, bowel preparation itself may decrease the patient’s
C. difﬁcile organism and spore concentrations. However,
manipulation with colonoscopy through an inﬂamed colon
can be difﬁcult and dangerous.
Here, we will outline the different methods of administra-
tion and how they affect the recipient’s preparation (Table 3).
FMT via colonoscopy
Recipients should take a large volume of colon lavage before
the procedure. The severity of the patient’s illness may limit
the ability to perform this step. In studies using colonoscopic
FMT, there are variations in the volume (100–1000 mL) and in
TABLE 3. Speciﬁcities related to route of faecal microbiota transplantation
Recipient preparation
Preparation and
administration of FMT Disadvantages and or risk
Situations requiring
precautions
Colonoscopy Large volume of bowel
preparation  loperamide
before and/or after procedure
Large volume (> 300 mL) in one procedure,
generally requiring sedation
Anaesthesia
Risk of colonic perforation
Cost
Severe colitis
Colonic distension
Severe comorbidities
Retention enema Variable volume of bowel preparation Small volume (50 mL) requiring four or ﬁve
consecutive days of rectal administration
Frequent stool losses Patients with diminished
rectal sphincter tone
Nasogastric or
nasojejunal tube
Proton-pump inhibitor the night
before and in the morning
No bowel preparation necessary
Generally small volume (25–50 mL) through a
nasoenteric tube requiring radiological
control before procedure
Discomfort of tube placement
Risk of aspiration and vomiting
Diarrhoea after the procedure
Gastroparesia
Motility disorder
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the site of infusion [2]. However, larger volumes seem to give
better results than small volumes. An administered volume of
< 200 mL gave a resolution rate of 80% and a relapse rate of
6.2%, whereas a volume of > 500 mL gave a resolution rate of
97.3% and a relapse rate of 4.7%. The use of < 50 g of faeces
was associated with resolution and relapse rates of 82.8% and
3.8%, respectively, whereas > 50 g of faeces gave resolution
and relapse rates of 86.2% and 1.0%, respectively [16,24].
Placement of the transplanted microorganisms into the
terminal ileum may theoretically aid in longer retention of
the FMT, given the presence of the ileocaecal valve. Some
instill the material on scope withdrawal, distributing it
throughout the colon, whereas others instill the suspension
primarily into the proximal colon but also into other colon
segments with the worst inﬂammation or most extensive
diverticulosis.
Orenstein et al. [17] have described their modalities. They
perform a standard colonoscopy, and, when the maximal
extent (e.g. terminal ileum or cecum) has been reached, the
homogenized faecal preparation is instilled via the working
channel of the colonoscope. After infusion, van Nood et al.
[18] recommended withdrawing swiftly, aspirating air only
from the distal left colon, sigmoid and rectum for patient
comfort. Some centres give two tablets of loperamide to the
recipient when the procedure is completed and 6 h later or
approximately 1 h before the procedure to maximize reten-
tion of the donated faeces [19,25]. Finally, FMT recipients are
reminded not to resume taking the antibiotics that they were
taking for CDI, and that they can resume their normal activities
on the following day.
Rectal enema
Prior to colonoscopy, FMT was most commonly performed
via enema. Distal colonic FMT by retention enema and rectal
tube instillation continues to be popular, owing to its
simplicity, low risk, and low cost. The preparation of the
donor, recipient and sample are similar to those for
colonoscopic instillation, except for the volume, which is
often lower, and a bowel lavage, which is generally avoided.
In addition, the procedure may require up to 5 days of
infusion to achieve the instillation of at least 200–300 mL of
faeces [26]. In the largest reported series, of 27 patients, 93%
were cured with a sample of 150 g of fresh faeces
homogenized in 300 mL of sterile water and administered
by rectal retention enema [14]. Retention enema is safe,
simple, and inexpensive; however, the theory that rectal
repopulation of the microbiota will lead to proximal coloni-
zation has yet to be validated, and diminished rectal sphincter
tone in the elderly may compromise retention of the FMT
infusate, and decrease success [14].
FMT via gastric or duodenal infusion
Nasoenteric infusions are usually performed on a single
occasion, similarly to colonoscopic FMT; however, FMT via a
nasoenteral tube provides more extensive exposure of the
gastrointestinal tract to donor faeces and is less costly than
FMT via enema or colonoscopy. The principal disadvantages of
delivery via a nasoenteral tube are the discomfort and difﬁculty
associated with post-pyloric tube placement. In addition, the
transit of donor faeces may be impeded in the setting of an
ileus. Because of the aspiration risk, a smaller volume of
suspension (25–50 mL) is generally instilled [2]. Patients
undergoing this route of FMT administration are often given
a proton-pump inhibitor on the evening prior to FMT [1]. Most
studies using the upper gut route have not required the
recipient to perform the bowel preparation that is needed for
colonoscopy. The tube must be placed during fasting period
and position must be radiologicaly controlled before instilla-
tion of the donor faeces. Common sense requires administra-
tion in a patient sitting or inclined (> 30°). Once FMT is
performed in the upper gut, the tube is ﬂushed with normal
saline and removed. When an upper endoscope is used to
perform FMT, a larger volume of faeces may be administered,
as the sample is instilled beyond the pylorus into the distal
duodenum or jejunum if a paediatric colonoscope is used. In
the recently reported Dutch FECAL trial, the ﬁrst randomized
controlled trial comparing nasoduodenal FMT with standard
vancomycin treatment for recurrent CDI, the FMT recipients
were pretreated with 500 mg of oral vancomycin four times
daily for 4 days or 5 days before FMT, and it was discontinued
on the day of transplant. Screened healthy donors provided
≥50 g of faeces, which were mixed with 500 mL of saline and
infused through a nasoduodenal tube at a rate of 2–3 min per
50 mL. The ﬁrst four or ﬁve syringes were infused in
approximately 10 min. After a break of 10 min, the remaining
syringes were infused. The tube was ﬂushed with tap water
after infusion of the donor faecal suspension, and left in situ for
approximately 30 min after infusion. The tube was then
removed. Immediately after removal of the tube, lemonade
was offered to patients, and patients were monitored for ≥2 h
before being dismissed and advised to visit the toilet before
going home, because most patients had loose stools after
infusion of donor faeces [3].
From a physiological standpoint, gastric and post-pyloric
emptying have not been studied in the setting of FMT. It has
been established, in the context of tube-feeding, that gastric
emptying depends on the rate of infusion, intragastric pH,
enteral formula osmolarity, and the underlying disease. The
rate of pyloric drainage of a compound with an osmolarity of
337 mOsm/L delivered over a period of 20 min (such as an
enteral formula) is approximately 6 mL/min.
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On the basis of this knowledge, and given the fact that faecal
and plasma osmolarities are similar, a rate of infusion not
exceeding 6 mL/min may provide good tolerance. An FMT
volume of 50 mL would thus require an infusion of approx-
imately 8–10 min. The previously described adverse events,
such as diarrhoea, could then be averted [3].
Some publications have reported the efﬁcacy of FMT
performed via an oesogastroduodenoscopy. The procedure
is considered to be fast, safe, and less stressful for the patient
[15], but requires, like colonoscopy, the involvement of
endoscopists. In a recent feasibility study, FMT performed
with a frozen inoculum from unrelated donors was effective in
treating relapsing CDI. In this study, nasogastric administration
appeared to be as effective as colonoscopic administration.
To summarize, although the recent meta-analysis concluded
that lower gastrointestinal FMT via colonoscopy or enema may
be preferable to upper gastrointestinal delivery, more ran-
domized controlled trials are required to deﬁnitively answer
this question [2]. Currently, selection of the appropriate
delivery method may mainly rely on clinicians’ experience and
comfort with certain techniques, patient colon conditions,
comorbidities, and patient preferences.
Monitoring of recipients
Post-FMT faecal testing for C. difﬁcile toxins has been con-
ducted in only a small number of patients. This test may not be
of clinical importance, because C. difﬁcile toxins can persist for
several weeks after clinical improvement. Most faecal C. difﬁcile
toxin tests were negative in the patients who received the test,
and positive in those patients who did not respond to the FMT
procedure. Infectious Diseases Society of America/Society for
Healthcare Epidemiology of America guidelines do not
recommend C. difﬁcile testing in patients who do not have
symptoms, because patients can be colonized with C. difﬁcile
and not develop disease [27,28,29].
Data on the long-term outcome of FMT are very limited.
The follow-up of these patients in terms of efﬁcacy and
long-term tolerance is essential. Such measures may reveal
new diseases that can potentially be caused by FMT. It is also
important to keep the original data of the recipient. Some
centres contacted patients for follow-up during the year
post-FMT in order to determine the outcome of the treatment
[17].
Conclusion
FMT is a promising treatment option for CDI, and current
evidence indicates excellent efﬁcacy in terms of clinical
outcomes. Its limitations are the current lack of standardiza-
tion and uncertain long-term safety. Many questions must be
answered before FMT can be recommended as a routine
standard treatment for CDI. Deﬁning the status of FMT is
actually a challenging but complex regulatory issue, with
potential differences between countries. Furthermore,
although a legal framework for and standardization of FMT
are needed, the process must not become too restrictive,
preventing the use of FMT when it is required. Well-designed
randomized controlled studies and follow-up registries seem
to be essential to determine the efﬁcacy and safety proﬁle of
FMT, to deﬁne a standardized administration process, and to
determine long-lasting effects.
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